Mental and Behavioral Health

A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.

Once maternal major depressive disorder is disentangled from drug exposure, SSRIs carry little or no added risk in pregnancy, according to analysis.

A study finds treated diabetes prevalence climbs steadily for 5 years after antipsychotic start, even with brief exposure.

The approval is backed by pivotal phase 3 trials and carries boxed warnings for suicidal ideation in pediatric patients and abuse potential.

New case-control study finds that patients with type 2 diabetes and more severe depressive symptoms show higher cortisol, higher hemoglobin A1C, and lower insulin.

A new sibling-matched cohort study challenges earlier observational data, offering pharmacists evidence-based reassurance to share with pregnant patients.

HHS targets SSRI overuse, urging pharmacists and clinicians to reassess long-term therapy, use safer tapers, and expand nondrug care.

ECO 2026 data shows Wegovy cuts migraines, depression, and heart risk in menopausal women, as glucagon-like peptide-1s' demand challenges pharmacists.

FDA approves Caplyta to prevent schizophrenia relapse, cutting risk 63% with a stable metabolic profile.

Under a 12-month agreement, the Utah authorities granted companies permission to use generative AI to authorize medication refills for state residents.

The executive order mandates national priority vouchers for psychedelic drugs that have received breakthrough therapy designations.

Pharmacists face alarming burnout rates, but hobbies—from horses to sports—can help protect mental health and keep patient care safer.

A study finds prior-authorization bans do not boost buprenorphine retention for patients on private insurance.

GLP-1 diabetes drugs show promise in cutting addiction risk and overdose deaths, hinting at new options for substance use disorder prevention and care.

The FDA approves Bysanti (milsaperidone) for schizophrenia and bipolar I disorder, leveraging iloperidone bioequivalence, with key metabolic monitoring needs.

As pharmacists continue to take on greater clinical roles, the growing need to address mental health concerns is reaching a boiling point.

Lumateperone shows promising remission rates for major depressive disorder, offering hope for sustained relief in adults when combined with antidepressants.

Pharmacists play a vital role in integrating diabetes and depression care, enhancing patient outcomes through screening, individualized treatment, and collaborative approaches.

Researchers want to bolster evidence regarding the known link between maternal mental health and childhood nutritional status.

Tardive dyskinesia presents significant challenges for patients, but new FDA-approved treatments offer hope for improved management and quality of life.

FDA approves lumateperone as an adjunct therapy for major depressive disorder, offering new treatment options for this indication.

Research reveals no significant disparities in cardiovascular disease incidence linked to mental disorders after the COVID-19 pandemic.

The FDA approves Uzedy, a long-acting risperidone injection, enhancing treatment options for adults with bipolar I disorder and addressing unmet needs.

In pharmacies in predominantly Black and Latino neighborhoods, only 18% and 17% were likely to carry buprenorphine compared with White neighborhoods.

Pharmacies face significant challenges in filling buprenorphine prescriptions for telemedicine patients, impacting opioid use disorder treatment access and patient satisfaction.